FibroGen (NASDAQ:FGEN) Now Covered by StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of FibroGen (NASDAQ:FGEN) in a research note issued to investors on Thursday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

FGEN has been the subject of several other research reports. HC Wainwright upgraded shares of FibroGen to a “strong-buy” rating in a research note on Tuesday, December 17th. William Blair reissued a “market perform” rating on shares of FibroGen in a report on Wednesday, November 13th.

FibroGen Stock Down 4.1 %

FGEN opened at $0.46 on Thursday. FibroGen has a 52 week low of $0.18 and a 52 week high of $2.80. The business’s 50 day moving average is $0.49 and its two-hundred day moving average is $0.43. The firm has a market cap of $45.95 million, a price-to-earnings ratio of -0.37 and a beta of 0.75.

FibroGen (NASDAQ:FGEN) last announced its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.21. The business had revenue of $46.33 million for the quarter, compared to analyst estimates of $34.00 million. During the same quarter last year, the company posted ($0.52) EPS. Equities analysts expect that FibroGen will post -0.8 EPS for the current fiscal year.

Institutional Investors Weigh In On FibroGen

Institutional investors and hedge funds have recently bought and sold shares of the stock. Franklin Street Advisors Inc. NC increased its position in FibroGen by 100.0% during the 4th quarter. Franklin Street Advisors Inc. NC now owns 200,000 shares of the biopharmaceutical company’s stock worth $106,000 after purchasing an additional 100,000 shares in the last quarter. FMR LLC boosted its stake in shares of FibroGen by 21.8% during the 3rd quarter. FMR LLC now owns 383,258 shares of the biopharmaceutical company’s stock worth $153,000 after purchasing an additional 68,569 shares during the last quarter. Assenagon Asset Management S.A. purchased a new stake in shares of FibroGen during the third quarter worth about $307,000. Geode Capital Management LLC grew its holdings in shares of FibroGen by 3.1% during the third quarter. Geode Capital Management LLC now owns 1,083,521 shares of the biopharmaceutical company’s stock worth $433,000 after buying an additional 32,884 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its position in shares of FibroGen by 430.7% in the third quarter. JPMorgan Chase & Co. now owns 1,673,555 shares of the biopharmaceutical company’s stock valued at $668,000 after buying an additional 1,358,194 shares during the last quarter. Hedge funds and other institutional investors own 72.71% of the company’s stock.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.